Pfizer Inc. and partner BioNTech said that a trial of their Covid vaccine booster was 95.6% effective.
According to the biotech companies, the results were based on a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech Covid-19 vaccine in more than 10,000 individuals 16 years of age and older.
“In the trial, a booster dose administered to individuals who previously received the Pfizer-BioNTech primary two-dose series restored vaccine protection against Covid-19 to the high levels achieved after the second dose, showing a relative vaccine efficacy of 95.6% when compared to those who did not receive a booster”, the companies stated.
The companies plan to provide the data to the Food and Drug Administration (FDA), the European Medicines Agency and other regulators worldwide.